chemostabilitychartapril2013 formatted 2

7/30/2019 ChemoStabilityChartApril2013 Formatted 2

1/90

BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00 1/90

Activation Date: 2 March 2006Revised Date: 01 Apr 2013

BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

DRUG & STRENGTH(Storage Prior to Use,

Manufacturer, PreservativeStatus)

ReconstituteWith:

To Give: VialStability Product Product Stability SpecialPrecautions/Notes

Aldesleukin22 million units

(1.3 mg)(Novartis)

(F)(PFL)no preservative1

1.2 mL SWI1,2

direct diluent against

side of vial duringreconstitution1

do not shake1

18 million unit/mL(1.1 mg/mL)

1,2

48 h F1

50 mL D5W1

30 70 mcg/mL1

Less than 30 mcg/mL:dilute in D5W

containing humanalbumin 0.1%

2

48 h F1

- do not use in-linefilter

1,2

- avoid

bacteriostatic waterfor injection or NSdue to increasedaggregation

1

Alemtuzumab30 mg/mL

(Genzyme previouslyBayer)

3

(F)(PFL)do not shake

no preservative4

N/A filter NOT required4

30 mg/mL4

discard unusedportion

4

SC syringe5

discard at the end ofthe day F or RT

- do not shake6

100 mL NS or D5W4

8 h F or RT4

**(PFL)6

100 mL NS or D5W7 8 h F or RT6

**(PFL)6


2/90






ReconstituteWith:


Amifostine500 mg

(MedImmune)(RT)

no preservative

8

9.7 mL NS only8

50 mg/mL8

24 h F, 5 h RT8

2550 mL*NS only8

540 mg/mL:24 hF,

85 h RT

- discard cloudysolution

9

Amsacrine75 mg/1.5 mL(Erfa Canada)

(RT)no preservative

10

glass syringespreferred duringreconstitution;

max. time in plasticsyringe

10: 15 min

13.5 mL supplieddiluent (L-lactic

acid)1

transfer 1.5mL fromampoule into the

diluent vial10

5 mg/mL10

24 h RT10

PFL10

500 mL D5W10

(plastic or glasscontainer)

10

7 d F, 48 h RT10,11,12


3/90






ReconstituteWith:


Asparaginase13

(asparaginase E. coli)

10,000 units(Orphan

PharmaceuticalInternational)(F)

no preservative14

do not shake; roll toreconstitute

15,9

4 mL SWI16

Intradermal test

9

: Reconstitute with

5 mL SWI to give2000 units/mL

Transfer 0.1 mL to10 mL vial (or 12mL syringe)

Add 9.9 mL SWIroll to dissolve togive 20 units/mL

2 unit test dose =0.1 mL

(Note: the rest of thereconstituted vial

has a concentrationof2000 units/mL)

9

2500 units/mL13

48 h F, RT13

syringe13

14 d F17, 13

50 mL*NS or D5W17,11

14 d F,

17,112 d RT

17,18


4/90






ReconstituteWith:


Erwinia asparaginase(asparaginase Erwinia

chrysanthemi)10,000 units

(OrphanPharmaceuticalsInternational)

(F)no preservative

19


19

1-2 mL NS

19

10000-5000units/mL

15 min in originalcontainer; 8 h in a

glass or

polypropylenesyringe19

glass orpolypropylene

syringe19

8 h in a glass orpolypropylene

syringe19

PEG-asparaginase(pegasparagase)

(pegylatedasparaginase E. coli)

750 units/mL(Enzon)

(F)no preservative

20

N/A 750 units/mL20


20

IM: maximum volume2 mL; if greater than

2 mL use multiple

sites20

syringe: 4 h20,21

- discard cloudysolution

20

- do not shake20

- do not use ifstored out ofrefrigerator forgreater than 48 h

20

- do not use ifpreviously frozen

20

IV: 100 mL NS orD5W

20

bag: 4 h20,21


5/90






ReconstituteWith:


Azacit id ine

100 mg(Celgene)(RT)

no preservative22

4 mL SWI

22

shake vigorously22

25 mg/mL

22

8 h F,45 min RT22

SC syringe

22

8 h F, 45 min RT

23

Refrigeratedsyringes

23:

allow up to 30 minprior toadministration toreach a temperatureof approximately 20- 25C

discard syringe iftime elapsed at RTis greater than 30min

- discard if containslarge particles22

- re-suspendsyringe contentsbefore injection byvigorously rollingsyringe betweenpalms

22

BCG81 mg

(Sanofi Pasteur)(F)(PFL)

preservative24


24

3 mL supplieddiluent

24

record time ofreconstitution

10.5 8.7108CFU/vial

(Connaught

strain)24

2 h F, RT24

50 mL NS24

2 h F or RTafterreconstitution

24

**(PFL)24


6/90






ReconstituteWith:


BCG(Tice substrain)

50 mg = 1 to 8 x 108

CFU

(Hospira/Organon)(F)(PFL)no preservative

25

1 mL preservativefree NS forinjection

25

use reconstitutiondevice provided

allow to stand for afew minutes, then

gently swirl tosuspend

25

1 to 8108

CFU/vial25

2 h F (PFL)

25transfer from vial to60 mL syringe, rinse

vial with another 1 mL

NS. Add rinse tosame 60 mL syringe.qs to 50 mL with NS

25

2 h F25

- overfill unknown- protect fromlight

25

- do not filter

25


7/90






ReconstituteWith:


Bendamustine25 mg100 mg

(Lundbeck)(RT)(PFL)

no preservative26

25 mg vial:add 5 mL SWI

26

100 mg vial:add 20 mL SWI

26

shake well;dissolves completely

in 5 minutes26

5 mg/mL26

30 minutes26

500 mL NS26

0.2-0.6 mg/mL26

completeadministration within

24 h F, 3 h RT26

Bevacizumab100 mg/4 mL

400 mg/16 mL(Roche)(F)(PFL)

do not shakeno preservative

27

N/A 25 mg/mL27

discard unused

portion27

1.4-16.5 mg/mL28

100-250 mL NSonly

27,28

48 h F, RT18,27,28

- do not shake27

Bleomycin15 units

(NB: dose in units only)(Bristol)

(F)no preservative

29

6 mL*NS29

2.5 units/mL 48 h F29

50 mL*NS29

24 h RT29

- no overfill30


8/90






ReconstituteWith:


Bleomycin15 units

(NB: dose in units only)(Hospira)(F)(PFL)

no preservative31

6 mL*NS or SWI31

2.5 units/mL31

48 h F, 24 h RT31

50 mL *NS, SWI31

24 h RT32

- no overfill33

Bleomycin15 units

(NB: dose in units only)(PPC)

(F)(PFL)no preservative

34

6 mL NS34

2.5 units/mL34

48 h F34

50 mL NS34

24 h RT34

Bortezomib3.5 mg

(Ortho Biotech formallyMillennium)(RT)(PFL)

no preservative35

3.5 mL NS35

1 mg/mL35

2d RT11,36

syringe35

8 h RT37


9/90






ReconstituteWith:


Brentuximab50 mg

(Seattle Genetics)(F)(PFL)

no preservative38

10.5 mL SWI38

Direct diluentagainst side of

vial duringreconstitution

38

Do NOT shake38

Use reconstitutedsolution within 24 h

F38

5 mg/mL38

24 h F38

0.4-1.8 mg/mL inNS, D5W,

Lactated Ringers(i.e. 100-250 mL)

38,39

24 h F38

Do NOT freeze38

Solution shouldbe clear toslightlyopalescent,

colorless andfree of visibleparticulates

38


10/90






ReconstituteWith:


Busulfan60 mg/10 mL

(Orphan Medical)(F)

no preservative40

N/A use 5-micron nylonfilter provided with

ampoule towithdraw drug40

6 mg/mL40


40

NS or D5W (dilute involume 10 times thebusulfan volume to ~

0.5 mg/mL)40


12 h F: NS40

8 h RT: NS, D5W

Cabazitaxel60 mg/1.5 mL

(sanofi-aventis canadaInc.)

(RT)41

- 4.5 mL of supplieddiluent (i.e. entirevial contents)

41

- slowly directdiluent againstinside of concentratevial duringreconstitution

41

- mix by repeatedinverting for 45seconds

41

- do not shake41

- let sit for 5 min41

10 mg/mL{41

1h RT41

NS orD5W{41

(e.g. 250 mL)

0.10 0.26 mg/mL41

completeadministration within 8

h RT41

- use 0.22 micronin-line filter

41

- use non-PVC

(non-DEHP) bagand tubing

41

- diluent contains13%(w/w) ethanolin water

41

- discard ifcrystallization

occurs41


11/90






ReconstituteWith:


CARBOplatin50 mg/5 mL

150 mg/15 mL450 mg/45 mL600 mg/60 mL

(Hospira)(RT)(PFL)

no preservative42

N/A 10 mg/mL42


42

0.3-10 mg/mL43

NS, D5W9,42

do NOT usealuminum-containingneedle or syringe

43

24 h RT,44

48 h F42

- do NOT usealuminum-containing needle,syringe or tubing

43

CARBOplatin50 mg/5 mL

150 mg/15 mL450 mg/45 mL

(Teva/Novopharm)

(RT)(PFL)no preservative

45

N/A 10 mg/mL45

discard unusedportion RT

45

0.5-10 mg/mL46

NS, D5W9,45,47

do NOT usealuminum-containingneedle or syringe

45

8 h RT45


45


12/90






ReconstituteWith:


Carmustine100 mg

(Bristol Labs)(F)

no preservative48

3 mL diluent(supplied)

48

diluent to reach RT,then dissolve drugwith 3 mL diluent;add 27 mL SWI

48


3.3 mg/mL in 10%ethanol

48

24 h F, 8 h RT48

glass48

or polyolefincontainer

9

500 mL NS or D5W48

24 h F: in glass,48

orpolyolefin container

9

use within 4 h ofreconstitution RT

48

- do not use ifproduct has oilydroplets

48

Cetuximab

100 mg/50 mL200 mg/100 mL(ImClone/BMS)

(F)do not dilutedo not shake

no preservative49

N/A 2 mg/mL49 discard unusedportion after 12 h

F, 8 h RT49

syringe49

sterile evacuatedcontainer or bag e.g.

polyolefin,polyethylene,ethylene vinyl

acetate, DEHPplasticized PVC, PVC

bag, or glass49

12 h F, 8 h RT49

12 h F, 8 h RT49

- administer with a0.2 or 0.22 micronlow protein bindingin-line filter

49

- normal salinemay be used toflush the line

49

- solution maycontain white

particulates whichdo not affectproduct quality

49


13/90






ReconstituteWith:


CISplatin10 mg/10 mL50 mg/50 mL

100 mg/100mL(Hospira)(RT)(PFL)

no preservative50

N/A 1 mg/mL50

48 h RT51

Less than or equal to60 mg: 100 mL NS*Greater than 60 mg:250 mL NS*

500 or 1000 mL *NS,D5-NS, D5-1/2S; D5-NS with mannitol; D5-

1/2S withmannitol

50,52; D5W-

1/3S with mannitol50

48 h RT51

- do NOT usealuminum-containing needle,syringe or tubing50


14/90






ReconstituteWith:


CISplatin10 mg/10 mL50 mg/50 mL

100 mg/100mL(Sandoz)(RT)(PFL)

no preservative53

N/A 1 mg/mL53

48 h RT54,53

Less than or equal to60 mg: 100 mL NS*Greater than 60 mg:250 mL NS*

NS; 0.45 % SodiumChloride with or

without mannitol55

2 L of D5 on one-halfor one-third NScontaining 37.5 g ofmannitol

53

24 h RT53


53

Cladribine10 mg/10 mL

(Janssen-Ortho)(F)(PFL)

no preservative56

N/A 1 mg/mL56


56

SC syringe57

48h F, end of dayRT

11,56,58,59

- shake vigorouslyto dissolve anyprecipitates fromrefrigeration

56

500 mL NS only56

Do NOT use D5W56

24 h RT56


15/90






ReconstituteWith:


Cassette:qs to 100 mL withbacteriostatic NSonly via SIMSDELTEC INC.MEDICATION

CASSETTES56 filterdrug and diluentthrough 0.22 micronfilter as each solutionis being introducedinto the cassette

at least 7 days56

SC syringe57

discard end ofday

11,59,60

Cladribine10 mg/10 mL

(PPC)(F)(PFL)

no preservative60

N/A 1 mg/mL60

discard unusedpotion

60

500 mL NS only

Do NOT use D5W

24 h RT


16/90






ReconstituteWith:


Cassette:qs to 100 mL withbacteriostatic NSonly via SIMSDELTEC INC.MEDICATION

CASSETTES60 filterdrug and diluentthrough 0.22 micronfilter as each solutionis being introducedinto the cassette

at least 7 days60

Clodronate300 mg/10 mL

(Oryx)(RT)

no preservative61

N/A 30 mg/mL discard unusedportion

61

500 mL NS or D5W61

12 h RT61


17/90






ReconstituteWith:


Cyclophosphamide200 mg500 mg

1000 mg

2000 mg(Baxter)


62

NS63

200 mg: 10 mL

500 mg: 25 mL1000 mg: 50 mL

2000 mg: 100 mL62

20 mg/mL62

48 h F,62,64,54

24 hRT

62

Less than or equal to1 g: 100 mL NS*

Greater than 1 g: 250

mL NS*high dose in BMT:may need 500 NS*

NS, D5W, D5NS62

72 h F,62,64

24 h RT62

CycloSPORINE50 mg/1 mL250 mg/5 mL

(Novartis)


65

N/A 50 mg/mL65


65

NS, D5W65

dilute to concentration

between 1:20 and1:100

65

dilute immediately priorto use

65

- polyoxyethylatedcastor oil/ethanolvehicle

65

- do NOTrefrigerate orfreeze

65

- use non-PVC bagand tubing

66


18/90






ReconstituteWith:


Cytarabine100 mg/1 mL

1000 mg/10mL2000 mg/20mL

(Hospira)(RT)(PFL)

no preservative67

N/A

record time of

puncture

100 mg/mL67

24 h RT67

100 mL*NS, Water forInjection, D5W,

Lactated Ringers67

72 h F, 24 h RT frominitial vial puncture

67

- do not use for ITinjection

Cytarabine100 mg(Pfizer)

(RT)(PFL)

no preservative68

NS, D5W, SWI orBWI

68

100 mg: 5 mL68

100 mg: 20mg/mL

68

Reconstitutedwith NS, D5W orSWI: discard at

end of day68,54

Reconstitutedwith BWI: 48 h

RT68

NS, D5W68

0.5 mg/mL: 48 hRT

68,54

8-32 mg/mL: 48 hRT

68,54

- for high doseuse, do not usediluent containing

benzyl alcohol68


19/90






ReconstituteWith:


CytarabineIT injection

67

100 mg/1 mL1000 mg/10mL2000 mg/20mL

(Hospira)(RT)(PFL)

no preservative67

N/A

record time ofpuncture

100 mg/mL67

24 h RT67

diluents containingpreservatives should

NOT be used forintrathecal

administration67

qs to 6 mL withpreservative free NS

69

use within 4 h of initialvial puncture

9,11

- auxiliary label70

:IT- label to includeroute in full (i.e.,

INTRATHECALinjection) attachedto both syringe andouter ziplock bag

70

CytarabineIT injection

100 mg(Pfizer)


68

Preservative-free

NS68

100 mg: 5 mL68

100 mg: 20

mg/mL68

discard at end of

day68,54

diluents containing

preservatives shouldNOT be used for

intrathecaladministration

68


69

use within 4 h of initial

vial puncture9,11

- auxiliary label70

:

IT- label to includeroute in full (i.e.,INTRATHECALinjection) attachedto both syringe andouter ziplock bag

70


20/90






ReconstituteWith:


CytarabineSC injection:

100 mg(Pfizer)


71

100 mg: 5 mL BWI71

100 mg:20 mg/mL

71

48 h RT71,72

Syringe 14 d F, 48 h RT72

- for high doseuse, do not usediluent containing

benzyl alcohol73- do not use for ITinjection

Dacarbazine100 mg200 mg

(Abraxis)


74

100 mg: 9.9 mLSWI

74

200 mg: 19.7 mL

SWI74

10 mg/mL74

72 h F, 8 h RT74

250-1000 mL*NS orD5W

24 h F, 8 h RT74

**(PFL)9,74

see SpecialPrecautions/Notes

Column

- protect containerfrom light duringstorage and

administration75

- overfill unknown

Dacarbazine200 mg600 mg

(Hospira)

(F)(PFL)no preservative76

200 mg: 19.7 mLSWI

76

600 mg: 59.1 mL

SWI

76

10 mg/mL76

48 h F, 8 h RT76

(PFL)77

0.193.0 mg/mL11,76

250-1000 mL*NS or

D5W

24 h F76

**(PFL)75

see SpecialPrecautions/NotesColumn

- protect containerfrom light duringstorage and

administration

75

- no overfill77,33


21/90

BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00 21/90Activation Date: 2 March 2006Revised Date: 01 Apr 2013




ReconstituteWith:


syringeDactinomycin

0.5 mg(Lundback)(RT)(PFL)

no preservative78

1.1 mLSWI(preservative

free)78

Do NOT use SWIwith preservative

(may formprecipitate)

78

0.5 mg/mL(500 mcg/mL)

78

discard at end ofday

10 mcg/mL orgreater

78

D5NS78

use within 4 h of initialvial puncture

54

- drug loss reportedwith some celluloseester membrane in-line filters

78

Dactinomycin0.5 mg

(Ovation)79


80

1.1 mLSWI(preservative

free)80

Do NOT use SWIwith preservative

(may formprecipitate)

80

0.5 mg/mL80

(500 mcg/mL)

24 h F, RT81

syringe80,82

24 h F, RT54

- do not filter80,82

DAUNOrubicin20 mg

(Erfa Canada Inc.)83

(RT)(PFL)

84

no preservative85

4 mL SWI83

5 mg/mL83,86

48 h F, 24 h RT85

100-250 mL inisotonic solution e.g.,

NS

83

no data for D5W85

24 h RT, 48 h F83


22/90





ReconstituteWith:


DAUNOrubicin20 mg

(Teva/Novopharm)(RT)(PFL)

no preservative87

4 mL SWI87

5 mg/mL87

24 h RT, 48 h F87

(PFL)87

100-250 mLNS or D5W

9

48 h F, 24 h RT87

**(PFL)87


23/90





ReconstituteWith:


Degarelix120 mg vial

(Ferring)(RT)


88

3 mL SWI (includedsolvent) per vial

88

do NOT usebacteriostatic waterfor injection

88

swirl gently; keepvial vertical at alltimes

88

reconstitution maytake up to 15 min

88

40 mg/mL88

2 h RT88

SC syringe88

2 h RT89


24/90





ReconstituteWith:


Degarelix80 mg vial(Ferring)

(RT)do not shake

88

no preservative88

4.2 mL SWI(included)

88

do NOT use

bacteriostatic waterfor injection

88

swirl gently; keepvials vertical at alltimes

88

reconstitution maytake up to 15 min

88

20 mg/mL88

2 h RT88

SC syringe88

2 h RT89

Denosumab120 mg/1.7 mL

(Amgen)(F)(PFL)


90

N/A 71 mg/mL90


90,90,91,54

sc syringe90

use within 4 h of initialpuncture

54

- do not use ifsolution is cloudy;trace amounts oftranslucent to whiteproteinaceousparticles areacceptable

90

- avoid vigorousshaking

90

- bring to roomtemperature 15-30minutes prior toadministration

90


25/90





ReconstituteWith:


Dexrazoxane250 mg500 mg(Pfizer)

(RT)

no preservative92

supplied diluent92

:250 mg: 25 mL500 mg: 50 mL

10 mg/mL92

6 h F92

empty viaflex bag92

6 h RT93

Dexrazoxane (sameformulation, no

diluent provided)250 mg500 mg(Pfizer)(RT)

94

no preservative

SWI94

250 mg: 25 mL500 mg: 50 mL

10 mg/mL94

30 min RT/4 h F94

MUST BE FURTHERDILUTED With

Lactated RingersInjection to 1.3 3.0

mg/mL94

1 h RT/4 h F94


26/90





ReconstituteWith:


DOCEtaxel20 mg/2 mL80 mg/8 mL

160 mg/16 mL

(Hospira)(F,RT)(PFL)

preservative95

n/a 10 mg/mL95

20mg/2 mL vial:discard unused

portion91,95

______________

80 mg/8 mL or160 mg/16 mLvial (maximumnumber ofpunctures: up to 3doses can beremoved when aventing needle is

also inserted i.e.,6 puncturestotal)

96

14 d F**(PFL)

91,95

0.3-0.74 mg/mL95

(250 mL NS orD5W

95)

completeadministration within4 h F,

9548 h RT

95,91

- use non-PVC(non-DEHP) bagand IVadministration set

95

- do not use chemodispensing pins

97


27/90





ReconstituteWith:


DOCEtaxel20 mg/0.5 mL80 mg/2 mL

(sanofi-aventis)

(F, RT) (PFL)no preservative

98

supplied diluent :- if vials were

refrigerated, allow towarm for 5 min at

RT. Withdraw entirecontents of the

diluent and inject theentire contents of

the syringe into thecorresponding

concentrate vial. Mixby repeated

inversions for 45

sec.DO NOT SHAKELet sit for 5minutes

98

10 mg/mL98

48 h F, RT98

0.3-0.74 mg/mL98

(250 mL NS or D5W98

completeadministration within4 h F

9848 h RT

91,91,99

- use non-PVC(non-DEHP) bagand IVadministration set

98

DOXOrubicin10 mg50 mg150 mg

(Hospira)(RT)(PFL)

no preservative100

NS, SWI, D5W100

(NS reconstitution

takes longer)10 mg: 5 mL

50 mg: 25 mL150 mg: 75 mL

2 mg/mL100

48 h F, 24 hRT

11,100

syringe100

48 h F, 24 h RT11,101


28/90





ReconstituteWith:


DOXOrubicin10 mg/5 mL20 mg/10 mL50 mg/25 mL

200 mg/100 mL

(Teva/Novopharm)(F)(PFL)

no preservative102

N/A


2 mg/mL 8 h102

syringe102

100 mL NS*

48 h F, 24 h RT102

from initial vial

puncture

DOXOrubicin10 mg/5 mL50 mg/25 mL

200 mg/100 mL(Pfizer)

(F)no preservative103

N/A 2 mg/mL103


103,54

syringe103

100 mL NS*

48 h F, 24 h RT103


29/90

BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00 29/90Activation Date: 2 March 2006

Revised Date: 01 Apr 2013




ReconstituteWith:


DOXOrubicinPegylated Liposomal

20 mg/10 mL50 mg/25 mL

(Janssen)(F)

no preservative104

N/A 2 mg/mL104


104

Less than 90 mg: 250mL D5W only

104

Greater than or equalto 90 mg: 500mL

D5W only104

24 h F104

- do not filter104

DOXOrubicinPegylated Liposomal

20 mg/10 mL50 mg/25 mL

(Schering)

(F)no preservative105

N/A 2 mg/mL105


105

Less than 90 mg: 250mL D5W only

105

Greater than or equal

to 90 mg: 500mLD5W only

24 h F105

- do not filter105

Epirubicin10 mg/5 mL20 mg/10 mL50 mg/25 mL

150 mg/75 mL200 mg/100 mL(Novopharm)


106

N/A106

2 mg/mL106

8 h F, RT106

syringe106

48 h F, 24 h RTFrom initial vial

puncture106


30/90






ReconstituteWith:


Epirubicin10 mg/5 mL50 mg/25 mL

200 mg/100 mL(PPC)


107

N/A


2 mg/mL107

8 h107

syringe107

48 h F, 24 h RTFrom initial vial

puncture107

100 mL *NS or D5W 2 d F, RT:NS or D5W

107,91

Epirubicin10 mg/5 mL50 mg/25 mL

200 mg/100 mL(Pfizer)(F)(PFL)

no preservative108

N/A


2 mg/mL108

8 h108

syringe108

48 h F, 24 h RT frominitial vial puncture

108

100 mL*NS or D5W9

2 d F, RT: NS orD5W

51


31/90






ReconstituteWith:


Etoposide100 mg/5 mL

500 mg/25 mL1000 mg/50 mL

(BMS)(RT)

preservative109

N/A 20 mg/mL109

14 dRT

9,11,110,111,112

0.2 0.4 mg/mL109

500 mL*NS or D5W109

0.2 mg/mL:48 h RT

11,109

0.4 mg/mL:

24 h RT109

- use non-PVC bagand tubing only

Etoposide100 mg/5 mL

200 mg/10 mL500 mg/25 mL1000 mg/50 mL

(Teva/Novopharm)(RT)(PFL)no preservative

113

N/A 20 mg/mL113


113

NS

Stability isconcentration

dependent

0.2-0.3 mg/mL:7 d F

1142 d RT

115,114

0.4-0.5 mg/mL:1 d F

1141 d RT

1140.6-

9.0mg/mL :

generally unstable9.5 mg/mL:2 d F

1141d RT

114

10-12 mg/mL:7 d F

1142 d RT

115,114

- use non-PVC bagand tubing only

D5W113

4 h RT113,116


32/90






ReconstituteWith:


Fludarabine50 mg

(Berlex)(F)

no preservative117

2 mL SWI117

25 mg/mL117

48 h F or RT11,51

dilute to maximum of1 mg/mL

117,118

100 mL*NS or D5W117

48 h F, RT11,51

Fludarabine50 mg

(Teva/Novopharm)(F)

no preservative119

N/A 25 mg/mL119


119

dilute to maximum of1 mg/mL

119

100 mL*NS or D5W

48 h F, 24 h RT119


33/90






ReconstituteWith:


Fluorouracil5000 mg/100 mL

(Hospira)(RT)(PFL)

no preservative120

N/A 50 mg/mL120

8 hRT120,121

syringe11

48 h RT11,18,121

2-10 mg/mL inD5W

120,121

50-1000 mL*D5W

24 hRT120,121

CIVI: ambulatorypump

121

complete within8 d

9,11,122

syringe 4 h RT91

Fluorouracil

500 mg/10 mL5000 mg/100 mL

(Sandoz)(RT)(PFL)

no preservative123

N/A 50 mg/mL123

4 h RT91

D5W123

24 h RT123


34/90






ReconstituteWith:


CIVI: ambulatorypump

complete within8 d

9,11,122

Gemcitabine200 mg

1000 mg2000 mg

(Accord Healthcare)(RT)

no preservative124

200 mg: 5 mL NS1000 mg: 25 mL NS

2000 mg: 50 mLNS

124

38 mg/mL124

24 h RT124

0.1 mg/mL - 10mg/mL NS

124

48 h RT125,111

Gemcitabine200 mg

1000 m g(Eli-Lilly)

(RT)no preservative

126

200 mg: 5 mL NS1000 mg: 25 mL

NS126

38 mg/mL126

48 h RT126,127

syringe126

48 h RT,11,126,127

0.110 mg/mLNS

126,127

48 h F, RT11,126,127


35/90






ReconstituteWith:


Gemcitabine200 mg

1000 mg2000 mg(Hospira)

RT128

no preservative

129

200 mg vial: 5 mLNS

1000 mg vial: 25 mLNS


128

38 mg/mL128

48 RT128,130,54

syringe128

24 h RT128,130


128,130

48 h RT130,54

Gemcitabine200 mg

1000 mg

(Teva/Novopharm)RTno preservative

131

200 mg vial: 5mLNS

1000 mg vial: 25 mLNS132

38 mg/mL132

24 h RT132


132

24 RT132

Gemcitabine200 mg

1000 mg(Sandoz Standard)

RTno preservative

133

200 mg vial: 5 mLNS


133

38 mg/mL133

48 h RT133,134

syringe133

48 h RT133,135,134

0.1 mg/mL - 38mg/mL NS or

D5W133,136

48 h RT11,137


36/90




37/90






ReconstituteWith:


IDArubicin5 mg10mg

(Pfizer)


138

5 mg: 5 mL SWI138

10 mg: 10 mL

SWI138

vial contents undernegative pressure

138

do NOT use BWI toreconstitute

138

1 mg/mL138

48 h F,24 h RT

138

**(PFL)138

syringe138

48 h F, 24 h RT138

- avoid alkalinesolutions

138

IDArubicin PFS5 mg/5 mL

10 mg/10 mL20 mg/20 mL

(Pfizer)(F)(PFL)

no preservative138

N/A 1 mg/mL138

24 h RT,48 h F

**(PFL)138

syringe138

4 hours from initialpuncture

91

- avoid alkalinesolutions138

IDArubicin5 mg/5 mL

10 mg/10 mL20 mg/20 mL

(PPC)(F)(PFL)

no preservative139

N/A 1 mg/mL139

discard unusedsolution

139

syringe139

4 hours from initialpuncture

91

- avoid alkalinesolutions

139


38/90






ReconstituteWith:


Ifosfamide1000 m g3000 mg(Baxter)(RT)

9

no preservative140

1000 mg: 20 mLSWI

140

3000 mg: 60 mLSWI

shake well

50 mg/mL140

48 h F11,140

0.620 mg/mL140

5001000 mL*NS,D5W, D5-NS,

D5-1/2NS, LactatedRingers

9,140

72 h F140

24 h F, RT when mixedwith mesna

9

D5W or LactatedRingers when mixed

Ifosfamide1000 mg3000 mg

(PPC)(RT)

no preservative141,141

1000 mg: 20 mLSWI

3000 mg: 60 mLSWI

141

shake well

50 mg/mL141

72 h F,24 h RT

141

0.6-20 mg/mL141

500-1000 mL *NSD5W; LactatedRingers141

72 h F24 h RT

141

24 h F, RT when mixedwith mesna

9

D5W or LactatedRingers when mixed

Iniparib100 mg/10 mL(sanofi-aventis)

(F)no preservative

142

N/A 10 mg/mL discard unusedportion

142

250 mL NS, D5W

dilute to 250 mL finalvolume by

withdrawing volumefrom bag equal to

volume of drug to beadded*

142

24 h RT142

- *may also useempty IV bag andqs to final volumeof 250 mL with NS,

D5W142


39/90






ReconstituteWith:


Interferon Alfa -2b18 million units/3 mL

(Schering)(F)(or up to 7 days at

RT before use)143

preservative144

N/A 6 millionunits/mL

143

48 h F11,143

syringe143

2 d F11,145

Greater than or equalto 0.3 million IU/mL

143

50 mL NS143

24 h F, RT145

Interferon Alfa -2b10 million units/1 mL

25 million units/2.5 mL(Schering)

(F)(or up to 7 days atRT before use)

143

preservative144

N/A 10 millionunits/mL

143

48 h F11,143

syringe143

2 d F11,145

0.3 million IU/mL143

50 mL NS143

24 h F, RT145


40/90






ReconstituteWith:


Interferon Alfa -2b10 million units

(Schering)(F)

143

no preservative (unless

reconstituted withBWI)144

1 mL supplieddiluent (SWI)

143

do not shake; roll to

reconstitute

143

10 millionunits/mL

143

24 h F143

syringe143

24 h F, RT145

Greater than0.1 million IU/mL

145

100 mL NS146

48 h RT9,11

1 mL BWI143


143

48 h F, RT11,143 syringe146 14 d F, 48 h RT11,146

100 mL NS146

48 h RT9,11

Interferon Alfa -2b18 million

units(Schering)(F)

143

no preservative (unlessreconstituted with

BWI)144

1 mL supplied

diluent143


143

18 million

units/mL143

24 h F143

syringe143

24 h F, RT145


41/90






ReconstituteWith:


> 0.1 million IU/mL147

100 mL NS146

48 h RT9,11

1 mL BWI143


143

48 h F, RT11

syringe143

14 d F11,146

100 mL NS146

48 h RT9,11


42/90






ReconstituteWith:


Ipilimumab

50 mg/10 mL200 mg/40 mL(BMS Canada)


148

N/A 5 mg/mL 24 h F,RT148

1 4 mg/mL in

NS, D5W 100 mL148

ORundiluted in emptyviaflex bag or glass

bottle

(allow vials to stand atRT for ~5 min prior to

withdrawal ofcontents)

148

24 h F,RT148

- do NOT shake148

- administer with0.2 or 0.22 lowprotein binding in-line filter

148

- vials may containtranslucent-to-white amorphousparticles

148

- discard if cloudyor has pronouncedcolour change(should be clear topale yellow)

148

- flush line with NSor D5W afterinfusion

148


43/90






ReconstituteWith:


Irinotecan 40 mg/2 mL100 mg/5 mL

500 mg/25 mL(Hospira)

(RT)(PFL)no preservative149

N/A 20 mg/mL149

2 days RT11,150,151

0.12 2.8 mg/mL149

500 mL9D5W

(preferred), NS149

24 h RT: D5W, NS149

48 h F: D5W(PFL)

149

- do NOTrefrigerate if inNS

152

Irinotecan 40 mg/2 mL100 mg/5 mL

(Pfizer)(RT)(PFL)

no preservative152

N/A 20 mg/mL152


152

0.12 2.8 mg/mL152

500 mL9D5W

(preferred), NS152

24 h RT: D5W, NS152

48 h F: D5W(PFL)

152

- do NOTrefrigerate if inNS

152

Irinotecan40 mg/2 mL100 mg/5 mL

(Sandoz)(RT)(PFL)

no preservative153

N/A 20 mg/mL153


153,54

0.12-2.8 mg/mL153

D5W (recommended)NS

153

24 h RT: D5W NS153

48 h F: D5W

153

(PFL)153


44/90






ReconstituteWith:


Ixabepilone15 mg

(contains 16 mg)45 mg

(contains 47 mg)

(BMS)(F)(PFL)no preservative

154


23.5 mL supplied

diluent

2 mg/mL

2 mg/mL

1 h RT154

0.2 0.6 mg/mL inLactated RingersInjection USP (usenon-PVC infusion

container)

154

6 h RT154

- use 0.2-1.2micron in-linefilter

154

- use non-PVC

(i.e., DEHP-free)administrationset

154

Leucovorin 50 mg/5 mL

500 mg/50 mL(Hospira)(F)(PFL)

no preservative155

N/A 10 mg/mL155

5 mL vial: discardunused portion

155

50 mL vial: 8 h

syringe156

7 d F156

48 h RT

115,156

0.05-10 mg/mL155

24 h RT155

: NS, D5W,Lactated Ringers,

Ringers

50-250 mL*NS,D5W, Lactated

Ringers, Ringers,D10W, D5-NS

8 h RT155

: D10W, D5-NS


45/90






ReconstituteWith:


Leucovorin 50 mg/5 mL

500 mg/50 mL(Teva/Novopharm)

(F)(PFL)157

N/A157

10 mg/mL157

5 mL vial: discardunused portion

157

50 mL vial:

discard unusedportion157

syringe 8 h157,11

0.060-1.0 mg/mL157

24 h RT NS, LactatedRingers, Ringers

157

50-250 mL* NS,D5W, Lactated

Ringers, Ringers,D10W, D10NS

157

12 h RT D5W,D10W

157

6 h RT D5NS157


46/90






ReconstituteWith:


Mechlorethamine10 mg

(OvationPharmaceuticals/Merck)

no preservative158

do NOT use ifdiscoloured or waterdroplets form in vial

before

reconstitution

158

10 mL SWI or NS158


1 mg/mL158

use within 4 h ofreconstitution

RT9,11

syringe158

completeadministration

4 h of reconstitutionRT

9,11,158

100 mL NS51,158

completeadministration within4 h of reconstitution

RT11,51,158


47/90






ReconstituteWith:


Melphalan50 mg

(GSK)(RT)(PFL)no preservative

159

10mL supplied

diluent

159

immediately afteradding diluent,

shake vigorously159


5 mg/mL159

2 h RT159

do NOTrefrigerate

0.1 0.45 mg/mL in

NS only

159

(e.g., greater than 45mg and less than orequal to 110 mg in

250 mL NS)*

complete

administration within60 min from time ofinitial reconstitution at

RT9

Mesna

1000 mg/10mL(PPC)(RT)

preservative160

N/A 100 mg/mL160 14 d F, RT11,160 Greater than or equalto 1mg/mL

160

NS or D5W

48 h F, 24 h RT160


48/90



Methotrexate50 mg/2mL

500 mg/20mL1 g/40mL5 g/200mL(Hospira)(RT)(PFL)

no preservative161

N/A 25 mg/mL161

50mg: discard

unused portion161

500mg, 1 g, 5 g:8 h F, RT

161

syringe 2 d F, RT9,162,163

- for high-dose

regimens (e.g., 1-8g/m

2as a single

dose)164

usepreservative-freemethotrexate

9


0.42 mg/mL

161

100 mL*NS, D5W

high dose (e.g., 1-8g/m

2as a single

dose)164,165-167

: 5001000 mL*

24 h RT

161

MethotrexateIT Injection

161:

Only preservative freemethotrexate may beadministered by theintrathecalroute

161

50 mg/2mL168

(Hospira)(RT)(PFL)

no preservative161

N/A 25 mg/mL161


161


69

use within 4 h of initial

puncture9,11

- auxiliary label

70:

IT- label to includeroute in full (i.e.,INTRATHECALinjection) attachedto both syringe andouter ziplock bag

70


49/90



Methotrexate50 mg/2mL

500 mg/20mL(Hospira)(RT)(PFL)

preservative161

N/A 25 mg/mL161

14 d F169,54

syringe 14 d F115,162

- high-dose

regimen(e.g., 1-8g/m

2as a single

dose)165-167

: usepreservative-freemethotrexate

9


0.42 mg/mL161

e.g., 100 mL*NS,D5W

161

24 h RT169

Mitomycin5 mg

20 mg(Teva/Novopharm)


170

SWI5 mg: 10 mL

20 mg: 40 mL

shake well170

0.5 mg/mL170

48 h F, RT11,170

(PFL)

170

syringe11

14 d F, 48 h RT11,170

0.02-0.04 mg/mL170

NS, D5W, sodiumlactate

170

3 h RT: D5W12 h RT: NS

24 h RT: sodiumlactate

170

Mitomycin5 mg

20 mg(BMS)


171

SWI5 mg: 10 mL20 mg: 40 mL

shake well171

0.5 mg/mL171

48 h F, RT11,171

(PFL)171

syringe9 14 d F, 48 h RT

9,18


50/90



0.020.04 mg/mL

NS, D5W, sodiumlactate

171

12 h RT: NS

3h: D5W24 h: sodium lactate

171


51/90






ReconstituteWith:


MitoXANTRONE20 mg/10 mL

25 mg/12.5 mL(Hospira)(RT)(PFL)

no preservative172

N/A 2 mg/mL172


172

0.2-0.6 mg/mL172

NS, D5W172

Greater than or equalto 50 mL*

172

NS: 24 h F, RT172

**(PFL)172


(Teva/Novopharm)(RT)(PFL)

no preservative173

N/A 2 mg/mL173


173

NS, D5W173


173

24 h RT173

**(PFL)174


(PharmaceuticalPartners of Canada)

(RT)no preservative

175

N/A 2 mg/mL175


175

NS, D5W2


175

24 h RT175


52/90



50 mcg/mL

100 mcg/mL500 mcg/mL

176

Use within 4 h176

NS176

Volume adjusted toensure a continuousinfusion of octreotide

at 25 mcg/hour176

24 h RT176

Octreotide

50 mcg/mL; 100

mcg/mL; 500 mcg/mL(Omega)(F)(PFL)

no preservative176

multidose vials (5mL):

200 g/mL(F)(PFL)

preservative176

N/A

200 mcg/mL

176

15 d F

176

NS

176

Volume adjusted toensure a continuousinfusion of octreotide

at 25 mcg/hour176

24 h RT

176

Octreotide50 mcg/mL; 100

mcg/mL; 500 mcg/mL

(Teva/Novopharm)(F)(PFL)

no preservativemultidose vials (5mL):

200 g/mL(F)(PFL)

preservative177

N/A 50 mcg/mL100 mcg/mL

500 mcg/mL177


177

sc syringe177

single use vials: usewithin 4 h

multidose vials: usewithin 14 d F

54,177

200 mcg/mL177

14 d F54,177

infusion: NS177

single use vials ormultidose vials: 24 h

RT177


53/90



Octreotide(Sandostatin)

1000 mcg/5 mL(Novartis)(F)(PFL)

preservative15

N/A 200 mcg/mL15

discard unused

portion178

50200 mL NS15,9

,179

SC infusion: adjustvolume to ensureinfusion rate of 25

mcg/h15

24 h RT15


54/90






ReconstituteWith:


Octreotide(Sandostatin)50 mcg/1 mL

100 mcg/1 mL500 mcg/1 mL

(Novartis)(F)(PFL)

no preservative15

N/A 50 mcg/mL100 mcg/mL

500 mcg/mL15


15

50-100 mL9,179

NS15

SC infusion: adjustvolume to ensureinfusion rate of 25

mcg/h15

24 h RT15

Octreotide(Sandostatin LAR)

10 mg20 mg

30 mg(Novartis)(F)(PFL)

no preservative178


gently run 2 mLdown sides of the

vial; do NOTdisturb for 25min, then swirlmoderately

15


10 mg: 5 mg/mL20 mg: 10 mg/mL

30 mg: 15 mg/mL15


15

deep intraglutealadministration only

15

use within 4 h of initialreconstitution

15,11

- do NOT shake


55/90



Ofatumumab100 mg/ 5 mL

1000 mg/50 mL(GlaxoSmithKline)


180

n/a 20 mg/mL180

discard unused

portion

1000 mL NS180

or

alternatively, 2000 mgdoses may be

supplied in2 x 500 mL NS

180

withdraw volumefrom bag equal to

volume of drug to beadded

180

48 h RT180

administer with

0.2 micron low

protein bindingin-line filter

180

do NOT shake;mix by slowinversion to avoidformation offoam

180

solution maycontain a small

quantity of drugparticles; do notadminister ifsolution is cloudyor discoloured

180


56/90






ReconstituteWith:


Oxaliplatin50 mg/10 mL100 mg/20 mL200 mg/40 mL

(Sanofi-Aventis)(RT)(PFL)

no preservative181

N/A 5 mg/mL181


181

0.2-1.3 mg/mL182

1.32 mg/mL181,182

250500 mL D5W181

do NOT use NS orother chloride-

containing solution181

do NOT usealuminum-containingneedle and syringe

181

0.2-1.3 mg/mL:14 d F, 48 h RT

183,115,182

1.3-2 mg/mL:

48 h F, 24 h RT181

- do NOT usealuminum-containing needle,syringe ortubing181


57/90






ReconstituteWith:


Oxaliplatin50 mg

100 mg(Sigmacon)

(RT)no preservative184

SWI, D5W:50 mg: 10 mL

100 mg: 20 mL


containingsolution

184

do NOT usealuminum-

containing needleand syringe

184

5 mg/mL184

24 h F184

500 mL D5W


containing solutions(degrades)

184

do NOT usealuminum-containingneedle and syringe

184

24 h F, 6 h RT184


184

PACLitaxel30 mg/5 mL

100 mg/16.7 mL300 mg/50 mL

(Biolyse)(RT)

185

no preservative186

N/A 6 mg/mL186

8 h RT186

0.3-1.2 mg/mL in NS,D5W

186

(e.g., 100-1000 mL)*

Completeadministration within

27 h RT187

;186

- use non-PVC(non-DEHP) bagand tubing with in-line filter

186

0.1 mg/mL in NS

188

44 h F, RT

188


58/90



0.012-0.12 mg/mL in

NS

189

devices with spikes(e.g., chemo

dispensing pins) maybe used with vials

190

16 h RT187


59/90






ReconstituteWith:


0.3-1.2 mg/mL in NS,D5W, D5NS, D5LR

191

(e.g., 100-1000 mL)*


27 h RT191

0.1-1 mg/mL in NS,D5W

189


100 mg/16.7 mL300 mg/50 mL

(BMS)


191

N/A 6 mg/mL191

30 mg/5 mL or100 mg/16.7 mL

vial: 48 h RT191;

54

300 mg/50 mLvial: 24 h RT

191

devices with spikes(e.g., chemo

dispensing pins)should not be used

with vials191

48 h F, RT189


191


100 mg/16.7 mL150 mg/25 mL300 mg/50 mL

(Hospira)(RT)(PFL)

preservative

192

N/A 6 mg/mL193

48 h RT193

;91

;194

0.3-1.2 mg/mL in NS,D5W,D5NS, D5LR

193

(e.g., 100-1000 mL)*

devices with spikes

(e.g., chemodispensing pins)

should not be usedwith vials

193


27 h RT193


193


60/90


PACLitaxel,nanoparticle, albumin-

bound (nab)100 mg(Abraxis BioScience

Canada, Inc.)(RT)(PFL)

no preservative195

20 mL NS195

- slowly directdiluent againstside of vial (i.e.,greater than orequal to1 min)duringreconstitution

195

- let stand forgreater than orequal to 5 min towet powder

195

- gently swirl orinvert for greaterthan or equal to 2min

195

5 mg/mL195

use immediately

(RT) or8 h F195

(PFL)

195

in empty sterile PVC

or non-PVC infusionbag195

48 h F plus an

additional 8 h RT

195,196

- each vial contains

900 mg humanalbumin195

- to preventfoaming, do NOTinject NS directlyonto the powder- some settling mayoccur. Use mildagitation toresuspend

195

- discard ifprecipitationoccurs

195

- in-line filters arenotrecommended

195


61/90


Pamidronate30 mg/10 mL

60 mg/10 mL90 mg/10 mL(Hospira)

(RT)no preservative

197

N/A 3 mg/mL

6 mg/mL9 mg/mL197

discard unused

portion

197

0.060.36 mg/mL NS,

D5W

197

e.g., 250 mL NS198

24 h F followed by 24 h

RT (total 48 h)

197

**(PFL)197

- do NOT mix with

calcium containingsolution (e.g.,Ringers)

197

Pamidronate30 mg/10 mL60 mg/10 mL90 mg/10 mL

(Omega)

(RT)no preservative

199

N/A199

3 mg/mL6 mg/mL

9 mg/mL199


199

0.060.36 mg/mL NS,D5W

199

e.g., 250 mL NS198

24 h F followed by 24 hRT (total 48 h)

199

**(PFL)199

- do NOT mix withcalcium containing

solution (e.g.,Ringers)

199

P id t


62/90


Pamidronate30 mg/10 mL

60 mg/10 mL90 mg/10 mL(PPC)(RT)

no preservative200

N/A200

3 mg/mL

6 mg/mL9 mg/mL200

discard unused

portion

200

NS; D5W200

Less than or equal to0.36 mg/mL

200

24 h RT200

- do NOT mix with

calcium containingsolutions200

Pamidronate30 mg/10 mL60mg/10 mL90 mg/10 mL

(Sandoz Canada)RT

no preservative201

N/A201

3 mg/mL6 mg/mL

9 mg/mL201


201,54

NS; D5W201

24 h RT201

- do NOT mix withcalcium containing

solution (e.g.,

Ringers)201

Panitumumab100 mg/5 mL200 mg/10 mL400 mg/20 mL

(Amgen)

(F)(PFL)do not shake

no preservative202

N/A 20 mg/mL202


202

Less than or equal to1000 mg: 100 mL

NS202

Greater than 1000mg:150 mL NS

202

1-10mg/mL202,203

24 h F, 6 h RT202,203

- administer with0.2 or 0.22 micronlow protein bindingin-line filter

202

- solution maycontain particulateswhich do not affectproduct quality

202

- do not administerif discoloured

202


63/90





ReconstituteWith:


Pemetrexed100 mg500 mg(Eli Lilly)

(RT)

no preservative204

100 mg: 4.2 mLpreservative-free

NS500 mg: 20 mL

preservative-freeNS

204

25 mg/mL204

24 h F, RT204

100 mLpreservative-free

NS204

do NOT mix with

calcium containingsolution (e.g.,Ringers)

205

24 h F, RT204

Porfimer15 mg75 mg(Axcan)

(RT)(PFL)

no preservative206

6.6 mL D5W31.8 mL D5W

206

record time of

reconstitution

2.5 mg/mL206

24 h F(PFL)

206

syringe206


11,207

**(PFL)206

- avoid contact withskin and eyes;protect exposedarea from light

206

Raltitrexed2 mg

(Hospira)(F, RT)(PFL)

no preservative208

4 mL SWI208

0.5 mg/mL208

24 h F, RT208

50250 mL NS,D5W

208

24 h F, RT208

Reovirus Serotype 3


64/90


Reovirus Serotype 3 Dearing Strain

REOLYSINDose (viral titre) in eachshipment may vary and

must be checkedclosely

(Oncolytics Biotech)(less than or equal to

-70 C)(PFL)no preservative

209

N/A209

dose (viral titre) in

each shipment mayvary and must bechecked closely

209

time from thawing

and dilution topatientadministrationshould be less

than 8 h; may beextended to 24 hif necessary

209

thaw at roomtemperature or in

fridge209

250 mL NS209

complete

administration within8 h of removal fromfreezer; may be

extended to24 h if necessary

209

refrigerate dilutedproduct until delivery to

treatment room209

- auxiliary label:

biohazard

209

riTUXimab100 mg/10 mL500 mg/50 mL

(Roche)(F)(PFL)

no preservative210

N/A 10 mg/mL210


210

1-4 mg/mL NS,D5W

210

(e.g., 250-500 mL)*

24 h F, 36 h RT210


65/90





ReconstituteWith:


Streptozocin1g

(Pfizer)(F)(PFL)

no preservative211

9.5mL NS, SWI,D5W

211

100 mg/mL211

48 h F,211

24 h RT

syringe211

48 h F, 24 h RT211

50-500 mL*NS, D5W,SWI

211

48 h F, 24 h RT211

Temozolomide100 mg

(Schering)(F)

do not dilute212

do not shake212

no preservative

212

41 mL SWI212

2.5 mg/mL212

14 h F, RT212

empty 250 mL PVCbag

212

14 h RT212

Temsirolimus30 mg/1.2 mL

(Wyeth)(F)(PFL)

213,214

no preservative215

1.8 mL supplieddiluent

213,214

10 mg/mL213,214

24 h RT213,214

(PFL)

213

250 mL NS213,214

Completeadministration within 6

h213,214

- use non-PVC bagand non-PVCtubing with in-linefilter

213,214



66/90





ReconstituteWith:


Teniposide50 mg/5 mL

(BMS)(RT)

preservative216

N/A 10 mg/mL216


50 500 mL NS orD5W for a final

concentration of 0.1-1mg/mL

216

0.1-0.4 mg/mL: 24 hRT

216

1 mg/mL: completeadministration within 4

h of preparationRT

216,217

- do not refrigerate- use non-PVC(non-DEHP) bagand tubing

216

- do not use if

precipitates216,217- excessiveagitation maycauseprecipitation

216

Thiotepa15 mg

(Bedford)(F)(PFL)

no preservative218

1.5 mL SWI218

filter through 0.22

micron filter218


10 mg/mL218

8 h F218

50 mL* NS218


219,218

**(PFL)218,220

- do not use ifprecipitates orremains opaque

218


syringe: reconstitutedsolution is hypotonicand must be furtherdiluted with NS prior

to use218

(finalconcentration of 0.5-1

mg/ml is nearlyisotonic)

221


219,218

**(PFL)218,220


67/90





ReconstituteWith:


ThiotepaIT injection:

15 mg(Bedford)(F)(PFL)

no preservative218

diluents containingpreservatives should

NOT be used forintrathecal

administration

1.5 mL SWI218

filter through 0.22micron filter

218


10 mg/mL218

8 h F218

qs to 6 mL withpreservative free

NS222


219,218

**(PFL)218,220

- auxiliary label69

IT- label to includeroute in full (i.e.,

INTRATHECALinjection) attachedto both syringe andouter ziplock bag

69

- cytotoxic223

- do not use ifprecipitates orremains opaque

218

Thyrotropin alfa1.1 mg

(Genzyme)(F)(PFL)

no preservative224

1.2 mL SWI224

swirl contents224

; donot shake

0.9 mg/mL224

24 h F224

syringe224

24 h F224



68/90





ReconstituteWith:

To Give: VialStability

Product Product Stability SpecialPrecautions/Notes

Tocilizumab80 mg/4 mL

200mg/10 mL400 mg/20 mL(Genentech)

(F)(PFL)

no preservative225

N/A 20 mg/mL225

6 h225,

18

100 mL NS

dilute to 100 mL finalvolume bywithdrawing volume

of NS from 100 mLbag equal to volumeof drug required fordose prior to addingdrug

225

24h F225

;6 h RT

226

- to preventfoaming: slowlyadd drug toinfusion bag andgently invert bag to

mix225


69/90





ReconstituteWith:


Topotecan4 mg

(Hospira)(F)(PFL)

single-use

no preservative227

N/A227

1 mg/mL227

6 h F, RT18

0.02 0.5 mg/mL227

24 h F, RT227

Topotecan4 mg

(Sandoz)(RT)(PFL)

no preservative228

4 mL SWI228

1 mg/mL228

24 h F, RT228

20 500 mcg/mL

NS, D5W228

24 h F, RT228

Trastuzumab

440 mg(Roche)

(F)preservative

229

20 mL suppliedBWI

229

swirl vial gently;allow to standundisturbed for 5min

1

21 mg/mL229

14 d F229

250 mL NS229

Do NOT use dextrosecontaining solutions

229

24 h F, RT229

- do not shake229

T t b 100 i l 5 L 20 / L230

8 h RT 24 h 250 L NS 0 45% f d f i l h ld


70/90


TrastuzumabEmtansine

100 mg, 160 mg(Genentech)


230

100 mg vial: 5 mLSWI

230

160 mg vial: 8 mLSWI

230

swirl gently untilcompletelydissolved; do NOTshake vigorously

230

20 mg/mL230

8 h RT or 24 hF

230

250 mL NS or 0.45%Sodium chloride

230

preferred: forimmediate use

230

24 h F230

- vials shouldremain refrigerateduntil use230

- 0.2 micron in-linefilter is required forinfusions preparedin NS

230

- minimum volumefor dilution is 250

mL230

Treosulfan1 g pre heat SWI to 50 mg/mL

23148 h RT

11,231undiluted

23248 h RT

11,231compatible with


71/90


1 g5 g

(medac)(RT)

no preservative231

pre-heat SWI to30C (not higher)shake vial carefullybefore adding thewarmed SWI1 g vial: 20 mL SWI,while slightlyshaking vial andsyringe; continueshaking thereconstituted

solution for another2 min

231

5 g vial: 100 mLSWI, while slightlyshaking vial andsyringe; continueshaking thereconstitutedsolution for another

2 min

231

50 mg/mL 48 h RT,

undiluted

dilute with NS or D5Win empty infusion bagfor final concentration

= 20 mg/mL231

48 h RT,

- compatible withpolytetrafluoroethylene filters231- may requirevigorous shaking toreconstitute

231

VinBLAStine10 mg/10 mL

(Hospira)(F)(PFL)

no preservative177

N/A 1 mg/mL177


177

syringe9,177

4 h F, RT233,234

- label with:WARNING: FORINTRAVENOUSUSE ONLY FATAL IF GIVENBY OTHERROUTES235,236

100 250 mL NS 24 h F RT233,234


72/90


100250 mL NS,

D5W

237

24 h F, RT



73/90





ReconstituteWith:


VinCRIStine2 mg/2 mL5 mg/5 mL(Hospira)(F)(PFL)

no preservative238

N/A 1 mg/mL238

8 h F, RT238

50 mL*NS, D5W238

24 h F, 6 h RT,238

**(PFL)238

- label with:WARNING: FORINTRAVENOUSUSE ONLY

FATAL IF GIVENBY OTHERROUTES

235,236

VinCRIStine1 mg/1 mL2 mg/2 mL5 mg/5 mL

(Teva/Novopharm)

(F)(PFL)preservative239

N/A 1 mg/mL239

14 d F, RT239

50 mL*NS, D5W239

72 h F, 24 h RT73

**(PFL)239

- label with:WARNING: FORINTRAVENOUSUSE ONLY

FATAL IF GIVENBY OTHERROUTES

235,236

Vinorelbine10 mg/1 mL50 mg/5 mL

(GSK)(F)(PFL)

no preservative240

N/A 10 mg/mL240


240

syringe: 1.5 3.0mg/mL in NS or

D5W240

24 h F, RT240

- label with:WARNING: FORINTRAVENOUSUSE ONLY FATAL IF GIVENBY OTHERROUTES

235,236



74/90


DRUG & STRENGTH

(Storage Prior to Use,Manufacturer, Preservative

Status)

Reconstitute

With:

To Give: Vial

StabilityProduct Product Stability Special

Precautions/Notes

0.5 2.0 mg/mL240

50 mL*NS, D5W,NS, D5NS,

Ringers, Ringers

Lactate240

24 h F, RT240

Vinorelbine10 mg/1 mL50 mg/5 mL

(Hospira)(F)(PFL)

no preservative241

N/A 10 mg/mL241


241

syringe: 1.5 3.0mg/mL in NS or

D5W241

24 h F, RT241


235,236

0.5 2.0 mg/mL241

50 mL* NS, D5W,NS, D5NS,

Ringers, RingersLactate

241

24 h F, RT241



75/90


DRUG & STRENGTH


Status)

Reconstitute

With:

To Give: Vial


Precautions/Notes

syringe: 1.5-3.0mg/mL in D5W or

NS242

24 h F, RT242

Vinorelbine10 mg/1 mL50 mg/5mL

(PPC)(F)(PFL)

no preservative242

N/A242

10 mg/mL242


242

0.5-2.0 mg/mL242

NS, D5W, NS,D5NS, Ringers,Ringers Lactate

242

24 h F, RT242

- label with:WARNING: FORINTRAVENOUSUSE ONLY FATAL IF GIVEN

BY OTHERROUTES

235,236

Vinorelbine

10 mg/1 mL50 mg/5mL(Pierre Fabre Pharma

Canada)(F)(PFL)

no preservative243

N/A

243

10 mg/mL

243

discard unusedportion243

syringe: 1.5-3.0mg/mL in D5W orNS

243

24 h F, RT

243


235,236


DRUG & STRENGTH R i T Gi Vi l P d P d S bili S i l


76/90


DRUG & STRENGTH


Status)

Reconstitute

With:

To Give: Vial


Precautions/Notes

0.5-2.0 mg/mL243

NS, D5W, NS,D5NS, Ringers,Ringers Lactate

243

24 h F, RT243

* Suggested volume based on usual dose range and any concentration range of stability data

** P f li h i i i i di li h i d M ifi i f i i f li h ( i


77/90


** Protect from light means minimizing exposure to direct sunlight over a storage period. More specific information on protection from light (eg, protecting

container and tubing during administration) will be indicated in the Under the Special Precautions/Notes column.

Centres are not to change the content locally but should forward suggestions to the Cancer Drug Manual staff.

Explanatory NotesStability data assume products prepared using standard aseptic technique in biological safety cabinet at low risk for contamination according tothe classification outlined in USP 797.

18,244

Vial stability: Stability of solution after first puncture or reconstituted solutionStorage temperature: If information states same stability with refrigerator and room temperature storage, then bold refrigerated as preferred (ie, tominimize growth of micro-organisms).

Cytotoxic: hazardous (see Policy II-20 for more details).Discard unused portion: Unused portion from single use vials should be discarded at the end of th

chemostabilitychartapril2013 formatted 2

Documents